Moderna sank -2.7% this afternoon, compared to the S&P 500's day change of -1.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Moderna has logged a -17.0% 52 week change, compared to 18.0% for the S&P 500
-
MRNA has an average analyst rating of buy and is -42.75% away from its mean target price of $181.35 per share
-
Its trailing earnings per share (EPS) is $2.61, which brings its trailing Price to Earnings (P/E) ratio to 39.8. The Health Care sector's average P/E ratio is 24.45
-
The company's forward earnings per share (EPS) is $-5.17 and its forward P/E ratio is -20.1
-
The company has a Price to Book (P/B) ratio of 2.33 in contrast to the Health Care sector's average P/B ratio is 4.16
-
The current ratio is currently 2.7, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $5.38 Billion and the average free cash flow growth rate is 0.0%
-
Moderna's revenues have an average growth rate of 0.0% with operating expenses growing at -51.8%. The company's current operating margins stand at 48.9%